DIalysis Symptom COntrol-Restless Legs Syndrome Trial

End Stage Renal Disease Clinical Trial

— DISCO-RLS  

Official title:

DIalysis Symptom COntrol-Restless Legs Syndrome Trial (DISCO-RLS Trial): A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03806530
• Other study ID #: DISCO_RLS_001
• Status: Completed
• Phase: Phase 3
• Start date: May 1, 2019
• Est. completion date: July 19, 2022

Study information

• Verified date: September 2022
• Source: Population Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The DISCO-RLS Trial is a randomized controlled trial to determine the safety and efficacy of pharmacologic therapy (ropinirole versus placebo and gabapentin versus placebo) for the treatment of Restless Legs Syndrome in patients with End Stage Renal Disease requiring hemodialysis.

Description:

The DISCO-RLS Trial is a randomized controlled trial to determine whether or not a fixed, low-dose therapy with ropinirole and/or gabapentin is safe and effective compared to either alone or placebo for the treatment of Restless Legs Syndrome in patients with End Stage Renal Disease receiving hemodialysis. DISCO-RLS will randomize a total of 80 participants. Participants will be randomized to 1 of 8 treatment sequences. Each sequence is composed of 4 periods and in each period participants will receive 1 of 4 possible combinations of study medications (gabapentin+ropinirole, gabapentin+placebo ropinirole, ropinirole+placebo gabapentin, placebo gabapentin+placebo ropinirole). Eligible participants will complete a 1-week Run-In period followed by 4 periods of 4 weeks each for a total of 16-week follow-up after randomization. A final study visit will be completed at the end of the 16 week follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: July 19, 2022
• Est. primary completion date: December 14, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age greater or equal to 18 years

• Has received at least 90 days of in-center hemodialysis at a frequency at least 3 times weekly

• RLS defined by 2012 Revised International Restless Legs Syndrome Study Group (IRLSSG) Diagnostic Criteria for RLS and of moderate severity defined by an IRLS score greater or equal to 10 with symptoms more than 2 days per week (see IRLS question #7)

• Provides informed consent

Exclusion Criteria:

• Hemoglobin<80g/L in the previous 4 weeks

• Intolerance to a dopamine agonists (e.g. pramipexole or ropinirole) or alpha 2 delta ligands (e.g. gabapentin, Neurontin, pregabalin, or Lyrica)

• Change in medication to treat RLS in previous 4 weeks

• Current pregnancy

• Planned kidney transplantation, travel or relocation in the next 6 months

• Unable to complete RLS symptom and HRQOL measurements due to language barrier or cognitive impairment

Related Conditions & MeSH terms

• End Stage Renal Disease
• Kidney Failure, Chronic
• Psychomotor Agitation
• Restless Legs Syndrome
• Syndrome

Intervention

Drug:
• Gabapentin
100 mg capsule
• Ropinirole
0.50 mg capsule
• Placebo Gabapentin
Placebo capsule
• Placebo Ropinirole
Placebo capsule

Locations

Country	Name	City	State
Canada	Nova Scotia Health Authority	Halifax	Nova Scotia
Canada	St. Joseph's Hamilton Healthcare	Hamilton	Ontario
Canada	The Ottawa Hospital	Ottawa	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Population Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	International Restless Legs Syndrome Study Group Rating Scale (IRLS)	The IRLS is a measure of severity of Restless Legs Syndrome. It includes 10 items, measured on a scale of 0-4. A score of 1-10 indicates mild severity, 11-20 indicates moderate severity, 21-30 is severe and 31-40 is very severe. Primary outcome is the difference in IRLS scores for each of the treatment regimens.	18 weeks (Baseline, Run-In, Follow-up)
Secondary	Restless Legs Syndrome-6 Scale (RLS-6)	The RLS-6 is a measure of severity of Restless Legs Syndrome for the past week. It includes 6 items, measured on a scale of 0-10. Each item is measured from no symptoms (score of 0) to very severe symptoms (score of 10). Secondary outcome is the difference in RLS-6 scores for each of the treatment regimens.	18 weeks (Baseline, Run-In, Follow-up)
Secondary	Patient Global Impressions (PGI)	The PGI is a measure of Restless Legs Syndrome symptom severity. It includes 1 item, measured on a scale of 1-7. 1 indicates mild severity, 3 indicates moderate severity, 5 is severe and 7 is very severe. Secondary outcome is the difference in PGI scores for each of the treatment regimens	18 weeks (Baseline, Run-In, Follow-up)
Secondary	Euro-Quality of Life Scale (EQ-5D-5L)	The EQ-5D-5L is a measure of health status. It includes 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale of 0-100 (0 being worst health and 100 being best health). The scale is measured by levels. Level 1 indicating no problems, 2 indicating slight problems, 3 indicating moderate problems, 4 indicating severe problems and 5 indicating extreme problems. Secondary outcome is the difference in EQ-5D-5L scores for each of the treatment regimens	18 weeks (Baseline, Run-In, Follow-up)
Secondary	Incidence of falls, fractures and hospitalizations/emergency room visits due to altered level of consciousness.	The total number of falls, fractures, or hospitalization/emergency rooms visits due to confusion/delirium or altered mental state.	18 weeks (Baseline, Run-In, Follow-up)